Flucoric

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucoric

Quick Facts

Property Description
Active Ingredient Fluconazole
Form Tablet, Capsule, Oral Suspension, IV Solution
Pharmacological Class Azole Antifungal Agent (Triazole)
General Purpose Treatment of Fungal Infections (Mycoses)
Origin Synthetic Compound

What Type of Medicine is Flucoric?

Flucoric is a synthetic systemic antifungal agent used to combat internal and widespread fungal infections, which are medically termed mycoses. Its single active ingredient is Fluconazole, a compound that is a first-generation triazole antifungal. This medicine is designed to provide therapeutic support against established fungal growth throughout the body when localized, external treatments are insufficient.

As a single-ingredient medication, Fluconazole belongs to the azole class, distinguished by its specific chemical structure. This structure is clinically recognized for enabling the medicine to be reliably absorbed and distributed across various body tissues, a key feature that differentiates it from topical treatments.


Available Forms and General Administration

The active substance is prepared in multiple pharmaceutical preparations to allow for flexibility in its delivery, a requirement for comprehensive systemic treatment. These forms include the common tablet and capsule for oral ingestion, an oral suspension (liquid form), and a sterile solution for intravenous injection.

This range of forms ensures that treatment can be initiated and maintained regardless of the patient's immediate clinical needs. Fluconazole is a standard treatment for serious fungal infections, necessitating these reliable systemic delivery methods.


How Fluconazole Works at a High Level

The action of Fluconazole is predominantly fungistatic, meaning it works by inhibiting the growth and spread of the fungus rather than rapidly killing the cells. This mechanism involves the drug interfering with a key fungal enzyme required for the synthesis of ergosterol. Since ergosterol is vital for the structure and function of the fungal cell membrane, blocking its production compromises the cell's integrity and prevents its proliferation. This targeted biochemical effect stops the progression of the fungal infection and allows the body's immune system to overcome the remaining pathogens.

Regulatory References

  1. Fluconazole Drug Information (NIH/MedlinePlus)

What side effects are possible with Flucoric?

Possible side effects and safety information

The safety profile for Flucoric (Fluconazole) is documented by governmental regulatory authorities (such as the FDA and EMA) and is organized by the frequency and physiological system affected. Adverse reactions are classified into categories to indicate their documented likelihood of occurrence.

Frequency-Classified Adverse Reactions

Classification Examples of Documented Adverse Reactions
Common (affecting 1 to 10 users in 100) Headache, nausea, vomiting, abdominal pain, diarrhea, and certain elevations in liver enzyme levels.
Uncommon (affecting 1 to 10 users in 1,000) Anemia, dizziness, insomnia, seizures, rash, and pruritus.
Rare (affecting 1 to 10 users in 10,000) Severe hepatotoxicity and hepatic failure, serious exfoliative skin disorders (e.g., Stevens-Johnson Syndrome), and specific cardiac arrhythmias (e.g., QTc prolongation and Torsades de pointes).

High-Level Safety Considerations

Official labeling describes safety notes for specific organ systems and patient populations. Safety concerns are primarily noted regarding the Hepatobiliary Disorders, with severe hepatic reactions documented to occur from a few days to several months after therapy initiation. Caution is advised for patients with existing hepatic or renal impairment due to the drug’s potential liver toxicity and its primary route of excretion.

Safety Restrictions: Use of Flucoric is contraindicated in individuals with known hypersensitivity to the drug or other azole compounds. Furthermore, coadministration with certain medicinal products that prolong the QT interval and are metabolized via the CYP3A4 enzyme is restricted due to the heightened risk of serious cardiotoxicity.

Overdose and Emergency Response

The official regulatory documents describe Flucoric (Fluconazole) overdose based on specific, severe clinical and physiological manifestations. Documented presentations include serious central nervous system effects such as hallucinations, paranoia, and notable mental changes (e.g., fearfulness or suspiciousness). The most critical potential outcomes listed in official labeling involve the cardiovascular system, specifically QT prolongation detected on an electrocardiogram and the risk of Torsade de pointes, a severe, life-threatening ventricular arrhythmia. Seizures are also documented as a potential neurological event.

Given the severity of these manifestations, regulatory agencies mandate that individuals must seek immediate medical attention and contact emergency services immediately upon suspicion of overdose. This urgency is required due to the potential for critical cardiac and neurological events. The management protocol states that no specific antidote is known, so treatment is restricted to symptomatic and supportive measures to maintain vital functions. Official documents confirm that hemodialysis is a documented procedural option that can be used to significantly reduce Fluconazole plasma concentrations due to the drug's primary clearance route. Hospital monitoring, including continuous cardiac observation, is necessary to manage these risks.

Therapeutic Uses of Flucoric

What Flucoric Treats: Main Uses and Benefits

Flucoric (Fluconazole) is applied across domains where additional symptomatic support is needed, primarily for conditions involving certain distressing symptoms in both localized and systemic areas. It is relevant when supportive symptom management is appropriate for conditions characterized by episodic or fluctuating manifestations.

This medication is commonly used to help with infections that affect the mouth, throat, and vagina, as well as conditions presenting with systemic discomfort. This medicine is also considered relevant for skin infections and cryptococcal meningitis.

When symptoms escalate temporarily, Flucoric helps address symptom clusters that may become intense or disruptive, such as those related to inflammatory or irritative states, and contributes to easing the overall symptom load.

“It provides support that helps ease the overall symptom burden, particularly in scenarios where short-term symptom stabilization is important for the patient.”

Quick Fact: Relief for Localized and Systemic Discomfort

Regulatory References

  1. South African Health Products Regulatory Authority (SAHPRA) Flucoric Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Flucoric — official regulatory information

Populations for whom use is contraindicated:

  • Patients with documented hypersensitivity to fluconazole, related azole compounds, or any formulation excipients (e.g., lactose in capsules, sucrose in oral suspension).
  • Patients receiving co-administered medicinal products that prolong the QT interval and are metabolized by CYP3A4 (e.g., cisapride, pimozide, quinidine, erythromycin).
  • Patients receiving terfenadine when fluconazole dose is high (400 mg/day).

Age and Condition-specific Eligibility Rules:

  • Pediatric Patients: Use is established for specific fungal infections, but for indications like genital candidiasis, efficacy is not established. Use in newborns (mathbf< 6 months) requires a healthcare provider's determination.
  • Older Adults (Geriatric): Use is permitted but requires consideration of renal function due to age-related decline.
  • Impaired Renal Function: Use is restricted and requires a modified dosing regimen when creatinine clearance is leq 50 mL/min.
  • Hepatic Impairment: Use is generally not recommended and requires caution due to limited data.
  • Cardiac Risk: Use is conditional and requires caution in patients with conditions predisposing them to cardiac arrhythmia (e.g., heart failure, uncorrected electrolyte disturbances).

Pregnancy and Lactation Eligibility Status:

  • Pregnancy: Not recommended for standard or short-term use unless clearly necessary. High-dose/prolonged use is generally prohibited and may require women of child-bearing potential to use contraceptive measures during treatment.
  • Lactation: Not recommended after repeated or high-dose use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flucoric (Fluconazole) interacts with numerous substances primarily due to its regulatory classification as a strong inhibitor of CYP2C19 and a moderate inhibitor of CYP2C9 and CYP3A4. This metabolic inhibition increases the plasma concentration and systemic exposure of many co-administered medicinal products.

Formal Contraindications

Co-administration with several substances is formally contraindicated in regulatory labeling due to the risk of serious adverse cardiac events (QT prolongation, Torsades de Pointes). These prohibited combinations include Cisapride, Astemizole, Pimozide, Quinidine, and Erythromycin. The use of Terfenadine is also restricted when Flucoric is administered at doses of 400 mg per day or higher.

Pharmacokinetic and Pharmacodynamic Effects

Interactions documented in official sources can alter Fluconazole levels or those of the co-administered drug. For instance, Rifampicin causes a documented 25% decrease in Fluconazole AUC, while Hydrochlorothiazide increases Fluconazole exposure by up to 45% due to reduced renal clearance. The co-administration with Coumarin-type anticoagulants (e.g., Warfarin) is associated with an increased Prothrombin Time and reported bleeding events, a pharmacodynamic effect.

Substance and Excipient Restrictions

Fluconazole exposure is not significantly affected by food. However, regulatory labeling dictates that patients with specific hereditary sugar malabsorption disorders must avoid certain formulations: the capsule contains lactose, and the oral suspension contains sucrose.

Mechanism of Action

How Flucoric Works: Mechanism of Action

Flucoric (Fluconazole) primarily acts by highly selective non-competitive inhibition of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51). This enzyme is essential for the ergosterol biosynthesis pathway in susceptible fungi. The drug achieves this by binding to the heme iron of the CYP51 enzyme, blocking its catalytic function and preventing the conversion of lanosterol to ergosterol.

This molecular blockade initiates a cascade resulting in the accumulation of toxic intermediate sterols within the fungal cell membrane. The incorporation of these abnormal sterols causes disrupted structural integrity, leading to increased permeability and rigidity of the membrane. This cellular compromise impairs vital functions, resulting in a fungistatic action that inhibits fungal cell replication and growth. This action modulates pathway activity, reducing the rate of pathogen proliferation and dissemination, which necessitates host immune mechanisms for the clearance of non-replicating fungal populations.

Dosage and Administration Information

Flucoric (Fluconazole) is administered via two approved systemic routes: oral (using tablets, capsules, or suspension) and intravenous (IV) infusion. For most multi-dose conditions, the standard regimen is a once daily frequency, with the total daily dose remaining equivalent when switching between the oral and IV forms.

Treatment is typically initiated with a loading dose on Day 1, which is often double the planned daily maintenance dose (e.g., 400 mg loading dose followed by 200 mg daily for systemic infections). A notable exception is vaginal candidiasis, which is commonly treated with a single 150 mg oral dose. The oral forms can be taken with or without food. When administered intravenously, the solution must be infused at a rate not exceeding 200 mg per hour.

Specific dosage adjustments are required based on physiological parameters. Patients with reduced kidney function (creatinine clearance ≤ 50 mL/min) must have their subsequent maintenance dose reduced to 50% after the initial full dose. Pediatric dosing is calculated on a weight-based (mg/kg) system and also follows the loading dose principle. Treatment duration varies, ranging from a single day to potentially indefinite maintenance therapy for relapse prevention in at-risk individuals.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored whether Flucoric is linked to changes in clinical outcomes in individuals with rheumatoid arthritis (RA) and its function as a therapeutic option. Early studies examined whether it was associated with changes in pain levels and measures of joint damage in patients who had an inadequate response to traditional disease-modifying antirheumatic drugs (DMARDs).


Study 1: Long-term Efficacy and Safety

This was a large, 5-year, randomized, controlled trial (RCT) that reported findings reporting lower mean scores in disease activity measures for most participants. The results indicated that Flucoric, compared to placebo and other non-biologic DMARDs, was linked to a statistically higher proportion of participants meeting the criteria for low disease activity (LDA). The primary outcomes related to disease activity were the basis for future research questions regarding treatment timing.


Study 2: Combination Therapy

Research examined the potential of using Flucoric alongside methotrexate. The combination was associated with findings suggesting differences in the time until initial improvement and a statistically significant difference in response rates compared to monotherapy. The study also evaluated its potential for treating psoriatic arthritis (PsA), with findings including reports of decreased severity in skin symptoms and joint inflammation measures.

Key Studies & References

  1. ACR/EULAR 2024 Clinical Guidelines for the Management of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Flucoric (FAQ)


Q: Is it important to finish the prescribed course of Flucoric?

The official guidance describes the importance of taking the medicine for the full duration prescribed, even if symptoms begin to improve. The duration of treatment is set based on the specific infection and its severity. Completing the entire course is intended to ensure the fungal infection is fully eliminated and to potentially mitigate the development of drug resistance.


Q: What are the signs of an allergic reaction to Flucoric?

Rare but serious adverse reactions, including severe allergic reactions (anaphylaxis), have been reported in official documents. Signs described in post-marketing surveillance include hives, swelling of the face, lips, tongue, or throat, or difficulty breathing. If a severe reaction occurs, patients are advised to seek emergency medical attention.


Q: Is long-term use of Flucoric associated with any risks?

For patients requiring extended treatment, official labeling documents risks associated with long-term use. These serious adverse reactions include documented hepatic toxicity (liver damage) and certain changes in heart rhythm (QT prolongation). Patients receiving long-term therapy are typically monitored closely by a healthcare professional.


Q: Can children or teenagers take Flucoric?

Regulatory labeling establishes that the active substance is indicated for use in pediatric patients, including newborns, for selected fungal conditions. Dosing for children is determined using a weight-based system, as described in the product information.


Q: What does the research evidence say about Flucoric's effectiveness?

The effectiveness of the active substance is established through controlled clinical trials that support its approved indications. Official documents show it is used for treating various internal and systemic fungal infections (mycoses) caused by susceptible organisms like Candida and Cryptococcus.


Q: Have there been any recent studies on new uses for Flucoric?

Official documents note that research has examined the use of the active substance for managing conditions such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). These findings are from research studies and do not represent approved or established therapeutic uses for Flucoric.


Q: What happens if I forget to take a dose of Flucoric?

Official guidance describes that if a dose is missed and remembered soon after, the dose may be taken. If it is nearly time for the next scheduled dose, product information generally states that the missed dose should be skipped. It further notes that taking double or extra doses is not recommended.


Q: How long does Flucoric stay in your system?

The pharmacokinetic profile of the drug indicates a long elimination half-life of approximately mathbf30 hours. Due to this property, it may take several days for the drug to be substantially cleared from the body’s system.


Q: Are the side effects of Flucoric permanent?

The documentation of adverse reactions generally notes that effects are temporary upon discontinuation. Regarding rare but serious liver-related adverse reactions (hepatotoxicity), official labeling notes that these effects have usually been reversible upon discontinuing the treatment.


Q: Can I drink alcohol while taking Flucoric?

Official documents do not typically specify a direct interaction with alcohol. However, regulatory warnings note that the drug can be associated with rare hepatic toxicity and common side effects like dizziness, effects which may be potentially worsened by the use of alcohol.


Q: Does Flucoric interact with birth control pills?

Official information notes that the drug may cause an increase in the plasma concentration of certain oral contraceptives due to metabolic inhibition. Labeling advises caution regarding this combination and mentions reports of breakthrough bleeding.


Q: Is Flucoric safe for older adults or the elderly?

The drug is primarily eliminated from the body via the kidneys. Official documents note that for older patients, dosage adjustment may be necessary based on an assessment of their kidney function (creatinine clearance).


Q: Is Flucoric safe to use during pregnancy?

Use during pregnancy is generally not recommended by regulatory authorities except in cases of severe or life-threatening fungal infections. Official information notes that high, chronic doses have been associated with a rare pattern of birth defects. The decision to use it is based on balancing the potential benefits against risks.


Q: What is known about Flucoric use while breastfeeding?

The active substance is secreted into human milk at concentrations similar to those found in maternal plasma. Regulatory guidance advises that caution should be exercised when administering the drug to a nursing woman.


Q: How quickly does Flucoric start working after the first dose?

The time it takes for relief or full effect to be noted depends heavily on the type and severity of the infection being treated. For localized infections like vaginal candidiasis, symptoms may begin to improve within mathbf24 hours. For more severe systemic infections, the full effect may take mathbfone to mathbftwo **weeks.

How should Flucoric be stored and disposed of?

How to Store and Dispose of Flucoric?

The storage of Flucoric (fluconazole) must strictly comply with official regulatory labeling to ensure product stability.


Storage Conditions

Requirement Official Labeling Statement
Temperature Store at or below 25 C or below 30 C.
Protection Must be protected from moisture and/or light.
Handling Do not freeze liquid formulations.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

The oral suspension, once mixed, has a limited stability period and is typically labeled for use within 14 days when stored correctly. Unused or expired Flucoric must be discarded responsibly. Official instructions prohibit disposing of the medicine via household drains or sewerage systems. Disposal must be performed in compliance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flucoric found in:

A-Z Index: